Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (Guangzhou Women and Children's Medical Center)
- Development stage
- Unknown
- Lead developer
- Guangzhou Women and Children’s Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
anti-CD19 CAR-T cells (Guangzhou Women and Children's Medical Center) is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen expressed on B cells. Developed by the Guangzhou Women and Children's Medical Center, this therapy is specifically being evaluated for the treatment of pediatric patients with refractory or recurrent lupus nephritis. The mechanism involves the depletion of B-lymphocytes, which are the precursors to antibody-secreting plasma cells; by eliminating these cells, the therapy aims to halt the production of pathogenic autoantibodies that drive the inflammatory destruction of the kidneys in systemic lupus erythematosus (SLE). This approach represents a potential paradigm shift from chronic immunosuppression to a one-time cellular immunotherapy aimed at achieving long-term drug-free remission in children who have failed traditional therapies.
- Other names
- anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (Guangzhou Women and Children's Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (Guangzhou Women and Children's Medical Center).